These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa. González-Pinto L, Alonso-García I, Blanco-Martín T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-García M, Lasarte-Monterrubio C, Guijarro-Sánchez P, Maceiras R, Moya B, Juan C, Vázquez-Ucha JC, Beceiro A, Oliver A, Bou G, Arca-Suárez J. J Antimicrob Chemother; 2024 Oct 01; 79(10):2591-2597. PubMed ID: 39073766 [Abstract] [Full Text] [Related]
11. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Cantón R. Antimicrob Agents Chemother; 2022 Mar 15; 66(3):e0216121. PubMed ID: 35007130 [Abstract] [Full Text] [Related]
13. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS, Castanheira M, Duncan LR, Mendes RE. Int J Infect Dis; 2021 Dec 15; 113():279-281. PubMed ID: 34670144 [Abstract] [Full Text] [Related]
14. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, Vagiakou E, Pournaras S. Int J Antimicrob Agents; 2021 Nov 15; 58(5):106440. PubMed ID: 34551356 [Abstract] [Full Text] [Related]
18. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. Antimicrob Agents Chemother; 2023 Jan 24; 67(1):e0128122. PubMed ID: 36541767 [Abstract] [Full Text] [Related]
20. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group. Eur J Clin Microbiol Infect Dis; 2021 Dec 24; 40(12):2533-2541. PubMed ID: 34291323 [Abstract] [Full Text] [Related] Page: [Next] [New Search]